Co-founder, the Thiel Fellowship
ADvantage Therapeutics Inc.
ADvantage Therapeutics develops targeted therapies that modulate amyloid-beta and tau protein pathways to address cognitive decline in Alzheimer's Disease. The company aims to enhance cognitive function and slow disease progression in patients suffering from this neurodegenerative condition.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$10.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- ADvantage Therapeutics develops targeted therapies that modulate amyloid-beta and tau protein pathways to address cognitive decline in Alzheimer's Disease. The company aims to enhance cognitive function and slow disease progression in patients suffering from this neurodegenerative condition.